This study is not accepting new patients
ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)
Summary
- Eligibility
- for people ages 12-100 (full criteria)
- Location
- at UC Irvine
- Dates
- study started
- Principal Investigator
- by Richard Lee, MD (uci)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Richard Lee, MD (uci)
Assistant Health Sciences Professor, Medicine
Details
- Status
- not accepting new patients
- Start Date
- Sponsor
- NeuroRx, Inc.
- Links
- VIP in the treatment of critical COVID-19: A prospective open label trial Intravenous Aviptadil Is Associated with Increased Recovery and Survival in Patients with COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial Brief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestinal Peptide
- ID
- NCT04453839
- Study Type
- Expanded Access
- Last Updated